TAN-1057 C: Difference between revisions
CSV import |
CSV import |
||
| Line 33: | Line 33: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:TAN-1057C.png|TAN-1057C | |||
File:TAN-1057D.png|TAN-1057D | |||
</gallery> | |||
Revision as of 20:55, 25 February 2025
TAN-1057 C is a pharmacological compound that belongs to the class of beta-adrenergic agonists. It is primarily used in the treatment of various cardiovascular diseases and respiratory disorders.
Pharmacodynamics
TAN-1057 C acts by stimulating the beta-adrenergic receptors present on the surface of various cells. This leads to an increase in the intracellular levels of cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA). PKA then phosphorylates various target proteins, leading to a variety of cellular responses.
Pharmacokinetics
After oral administration, TAN-1057 C is rapidly absorbed from the gastrointestinal tract. It is extensively metabolized in the liver by cytochrome P450 enzymes, and the metabolites are excreted in the urine and feces. The half-life of TAN-1057 C is approximately 4-6 hours.
Clinical Uses
TAN-1057 C is used in the treatment of various cardiovascular diseases such as hypertension, angina pectoris, and congestive heart failure. It is also used in the management of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
Side Effects
The most common side effects of TAN-1057 C include tachycardia, palpitations, tremors, and nervousness. Less common side effects include insomnia, nausea, and headache. Rare but serious side effects include cardiac arrhythmias, myocardial infarction, and stroke.
Contraindications
TAN-1057 C is contraindicated in patients with known hypersensitivity to the drug or any of its components. It is also contraindicated in patients with uncontrolled hypertension, severe cardiac disease, and hyperthyroidism.
Interactions
TAN-1057 C may interact with other drugs such as beta-blockers, calcium channel blockers, and monoamine oxidase inhibitors (MAOIs). Therefore, caution should be exercised when TAN-1057 C is used in combination with these drugs.
References
-
TAN-1057C
-
TAN-1057D
